UBS AM
CRNX icon

UBS AM’s Crinetics Pharmaceuticals CRNX Stock Holding History

UBS AM’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.57M Sell
202,395
-27,733
-12% -$1.03M ﹤0.01% 1402
2026
Q1 		$8.36M Buy
230,128
+4,286
+2% +$191K ﹤0.01% 1289
2025
Q4 		$10.5M Buy
225,842
+8,152
+4% +$363K ﹤0.01% 1100
2025
Q3 		$9.07M Sell
217,690
-117,106
-35% -$3.74M ﹤0.01% 1102
2025
Q2 		$9.63M Sell
334,796
-12,785
-4% -$395K ﹤0.01% 1372
2025
Q1 		$11.7M Buy
347,581
+22,305
+7% +$833K ﹤0.01% 1158
2024
Q4 		$16.6M Buy
325,276
+53,529
+20% +$2.99M ﹤0.01% 1033
2024
Q3 		$13.9M Buy
271,747
+10,767
+4% +$555K ﹤0.01% 1098
2024
Q2 		$11.7M Buy
260,980
+49,160
+23% +$2.27M ﹤0.01% 1073
2024
Q1 		$9.92M Buy
211,820
+148,645
+235% +$5.82M ﹤0.01% 1000
2023
Q4 		$2.25M Buy
63,175
+349
+0.6% +$10.7K ﹤0.01% 1636
2023
Q3 		$1.87M Buy
62,826
+49,081
+357% +$1.01M ﹤0.01% 1664
2023
Q2 		$221K Hold
13,745
– – ﹤0.01% 2551
2023
Q1 		$221K Sell
13,745
-12,321
-47% -$228K ﹤0.01% 2551
2022
Q4 		$477K Hold
26,066
– – ﹤0.01% 2190
2022
Q3 		$512K Buy
26,066
+12,321
+90% +$251K ﹤0.01% 2337
2022
Q2 		$256K Sell
13,745
-1,276
-8% -$25.5K ﹤0.01% 2515
2022
Q1 		$330K Sell
15,021
-7,951
-35% -$161K ﹤0.01% 2570
2021
Q4 		$653K Buy
22,972
+6,832
+42% +$168K ﹤0.01% 2437
2021
Q3 		$340K Hold
16,140
– – ﹤0.01% 2596
2021
Q2 		$304K Buy
16,140
+1,637
+11% +$28.8K ﹤0.01% 2644
2021
Q1 		$222K Hold
14,503
– – ﹤0.01% 2546
2020
Q4 		$205K Buy
14,503
+4,000
+38% +$55.7K ﹤0.01% 2496
2020
Q3 		$165K Sell
10,503
-22,751
-68% -$348K ﹤0.01% 2424
2020
Q2 		$583K Buy
+33,254
New +$567K ﹤0.01% 2053

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS AM's CRNX Position: Q2 2026 in Review

UBS AM reduced its Crinetics Pharmaceuticals (CRNX) stake by 12% in Q2 2026, selling an estimated $1.03M and leaving 202,395 shares worth $7.57M. The position accounts for ﹤0.01% of the portfolio, ranked #1402.

UBS AM first reported a position in CRNX in Q2 2020 and has held it in 25 quarters since. The position peaked at $16.6M in Q4 2024. 266 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • UBS AM held 202,395 shares of Crinetics Pharmaceuticals worth $7.57M as of Q2 2026.
  • UBS AM sold 27,733 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $1.03M.
  • Crinetics Pharmaceuticals made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #1402 holding.
  • UBS AM first reported a position in Crinetics Pharmaceuticals in Q2 2020 and has held it in 25 quarters since.
  • UBS AM's Crinetics Pharmaceuticals position peaked at $16.6M in Q4 2024.
  • 266 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.